Synergistic effects of HDAC inhibitor tucidinostat and ENT inhibitor dipyridamole in T-cell malignancies
Artículo
Acceso abierto
Artículo
DOAJ
Abstract Achieving both selectivity and cytotoxicity against cancer cells remains a major challenge in cancer therapy. Histone deacetylase (HDAC) inhibitors, such as tucidinostat, suppress tumor growth by epigenetically ...
LCC LCC:Medicine; TENDOlNjaWVuY2U~Idioma eng
Acceso abiertoRuta libre sin proxy. Acceso recomendado cuando no hay suscripción activa.
Open Access